Abstract: The present invention concerns the use of a radioiodinated phenolic compound of the formula wherein: m and n are independently 0, 1, 2 or 3, X is a group that is negatively or positively charged at physiological pH, R, R1, R2 and R3 are independently hydrogen, C1-C4 alkyl, or a carboxyl group, and I* is 123I, 131I or 125I, and its pharmaceutically-acceptable salts. The compound is formulated and used in vivo in an animal in brachytherapy in an implantable catheter. In addition, due to the rapid renal clearance of these compounds, they may be used to study renal function. A process to prepare these compounds is also disclosed.

Abstract: The present invention concerns the use of a radioiodinated phenolic compound of the formula wherein: m and n are independently 0, 1, 2 or 3, X is a group that is negatively or positively charged at physiological pH, R, R1, R2 and R3 are independently hydrogen, C1-C4 alkyl, or a carboxyl group, and I* is 123I, 131I or 125I, and its pharmaceutically-acceptable salts. The compound is formulated and used in vivo in an animal in brachytherapy in an implantable catheter. In addition, due to the rapid renal clearance of these compounds, they may be used to study renal function. A process to prepare these compounds is also disclosed.

Abstract: The invention relates to fibrin/fibrinogen binding conjugate comprising a fibrin/fibrinogen binding moiety, a substance capturing moiety capable of reversibly binding to a pharmaceutically active substance, and a pharmaceutically active substance, wherein the fibrin/fibrinogen binding moiety is bound to the substance capturing moiety, a kit for forming a depot for a pharmaceutically active substance and a method for producing a depot for a pharmaceutically active substance.

Abstract: The present invention relates to a liquid transparent tooth cleaning composition containing silica polishing components, humectant and water. The humectant includes sorbitol (a), glycerol (b) and polyethylene glycol (c) in a weight ratio of (a) to (b) to (c) of 10:(7 to 8):(0.5 to 1.5).

Abstract: Oral composition comprising a co-ground of at least two ingredients which are co-ground without the use of solvents and wherein the co-ground comprises each of at least two ingredients at a level of at least 5% by weight of the total weight of the co-ground, characterised in that the composition is an aqueous composition.

Abstract: The invention relates to a process for producing uniformly colored blue microcapsules, using oil-soluble dyes.

Abstract: A product for application to the skin includes a container and a composition within the container including a cosmetic or therapeutic active ingredient. Sometime after first use, the application surface of the composition changes from a first visual appearance to a second visual appearance due to a change in the composition.

Abstract: Disclosed is a safe and effective hair-growing agent comprising a protein kinase C-specific inhibitor.

Abstract: A composition and method for making a silicone composition is provided which comprises at least one polysiloxane or silicone resin, at least one molecular hook, and at least one linker.

Abstract: Cosmetic compositions containing in a cosmetically acceptable medium, at least one fixing and/or conditioning polymer and at least one amphoteric polymer comprising from 1 to 20 mol % of at least one monomeric unit chosen from (meth)acrylate and (meth)acrylamide types having at least one fatty chain, the fatty chain having from 8 to 30 carbon atoms. This combination may provide markedly improved cosmetic properties (disentanglement, softness) compared with the properties obtained with either of the constituents used alone. These compositions are used for washing and/or conditioning keratinous materials such as the hair or the skin.

Abstract: The oxidative hair treatment composition is made by mixing several components immediately prior to application on the hair. One component contains dehydroascorbic acid, its derivatives or salts or their mixture, is anhydrous or contains up to 10% by weight of water, and is a powder, granulate or tablet or micro-encapsulated or a suspension and another component is an aqueous, alcoholic or aqueous alcoholic preparation. In order to avoid an unpleasant mercaptan odor and provide a uniform treatment the method for permanently waving hair includes putting the hair into the desired form, treating it with a keratin-reducing agent, and then rinsing it, after which it is treated oxidatively with the above-described oxidative treatment composition and rinsed once again.

Abstract: A hair coloring composition suitable for application to hair by containing one or more hair substantive direct dyes, in a controlled evaporation rate vehicle, and on an optional polymeric ruboff shield, and a controlled viscosity to be reasonably free flowing yet not drip or cause build-up on the hair.

Abstract: A composition containing enhanced colloidal oatmeal which utilizes other avena sativa ingredients to neutralize the discomfort, irritation and inflammation of the skin, as well as maintaining normal skin, and can be used to treat many types of discomforts, including itching; due to poison ivy, oak and sumac, insect bites, sunburn, chicken pox, hives, prickly heat, chafing, and the like while maintaining the normal pH of the skin.

Abstract: A liquid makeup cosmetic comprising the following components (a), (b) and (c): (a) an acryl-silicone base graft  3 to 20% by weight copolymer, (b) a spherical fine particle  5 to 30% by weight powder, and (c) a low boiling silicone oil 10 to 70% by weight, and a liquid makeup cosmetic applicator which uses a brush as an applying means and which is charged therein with the liquid makeup cosmetic described above. Used are a mixed solution of an acryl silicone-base graft copolymer and decamethylcyclopentanesiloxane as the acryl-silicone base graft copolymer, an organic spherical powder of nylon, etc. or an inorganic spherical powder of magnesium silicate, etc. as the spherical fine particle powder and low polymerization degree dimethylpolysiloxane, etc. as the low boiling silicone.

Abstract: A method for enhancing the expression of aquaporin proteins by contacting aquaporin producing cells with interferon-&agr; is described. The method enables treatment of patients afflicted with disease states characterized by xerosis.

Abstract: The present invention provides methods and compositions for the therapeutic intervention of Parkinson's disease. More particularly, methods of making and sequestering dopamine are disclosed. Additionally, methods of genetically modifying donor cells by gene transfer for grafting into the central nervous system to treat defective, diseased or damaged cells are disclosed. Methods and compositions for carrying out such gene transfer and grafting are described.

Abstract: This invention concerns new configurations for biological switches and provides new methods and materials useful for regulating biological events in animal cells. The invention involves recombinant DNA constructs comprising DNA sequences derived from sequences encoding the proteins FRAP, Tor1, Tor2 and other proteins capable of binding to FKBP:rapamycin, other recombinant DNA constructs comprising DNA sequences encoding part or all of an FKBP protein, the proteins encoded by those constructs, cells (especially animal cells) transformed with one or more of the constructs, small molecules (multivalent multimerizing agents) which bind to and are capable of inducing multimerization of the chimeric proteins, and methods for preparing and using the foregoing, including methods involving the intramuscular delivery of such recombinant DNA constructs in AAV virus particles.

Abstract: The present invention provides method of making a protein hydrolysate formula and protein hydrolysate formulas made thereby for downregulating hypersensitivity and for promoting gut immune barrier, and methods of preventing or treating allergies, especially cow's milk allergy by combining the protein with probiotic gastrointestinal bacteria, especially Lactobacilli. The probiotics make it possible to influence the immunological balance, whereby allergy can be prevented by affecting the initiation mechanism of allergy. The present invention makes it possible to develop a person's tolerance of proteins by actively promoting a tolerogenic immune response. In addition, present invention provides for administering fragments of an allergen modified by probiotic gastrointestinal bacteria in order to desensitize a immune response to systemic hyporesponsiveness.

Abstract: Disclosed are modified red blood cells which function as deployment platforms for important biomolecules. Such modified red blood cells can confer, for example, in vivo protection against exposure to an otherwise lethal nerve agent.

Abstract: P-selectin has been demonstrated to bind primarily to a single major glycoprotein ligand on neutrophils and HL-60 cells, when assessed by blotting assays and by affinity chromatography of [3H]glucosamine-labeled HL-60 cell extracts on immobilized P-selectin. This molecule was characterized and distinguished from other well-characterized neutrophil membrane proteins with similar apparent molecular mass. The purified ligand, or fragments thereof (including both the carbohydrate and protein components), or antibodies to the ligand, or fragments thereof, can be used as inhibitors of binding of P-selectin to cells.

Abstract: The present invention is directed to humanized antibodies which bind human gp39 and their use as therapeutic agents. These humanized antibodies are especially useful for treatment of autoimmune diseases.

Abstract: A number of protein and glycoprotein antigens secreted by Mycobacterium. tuberculosis (Mt) have been identified as “early” Mt antigens on the basis early antibodies present in subjects infected with Mt prior to the development of detectable clinical disease. These early Mt antigens, in particular an 88 kDa secreted protein having a pI of about 5.2 and the sequence of SEQ ID NO:106, which is present in Mt lipoarabinomannan-free culture filtrate, a protein characterized as Mt antigen 85C; a protein characterized as Mt antigen MPT51, a glycoprotein characterized as Mt antigen MPT32; and a 49 kDa protein having a pI of about 5.1, are useful in immunoassay methods for early, rapid detection of TB in a subject. Preferred immunoassays detect the antibodies in the subject's urine. Also provided are antigenic compositions, kits and methods to useful for detecting an early Mt antigen, an early Mt antibody, and immune complexes thereof.

Abstract: Disclosed herein are methods and pharmaceutical formulations for administering vaccines to birds. In preferred embodiments, the invention provides methods of administering live pathogenic virus vaccines to birds in ovo, more preferably, during the last quarter of in ovo incubation. Interferon, more preferably, Type I interferon, may be advantageously administered in conjunction with live virus vaccines to decrease the pathogenicity thereof. Interferon must be provided at doses sufficient to protect against pathogenicity of the live vaccine, but not at doses so high as to prevent the host from mounting an active immune response. Further provided are pharmaceutical formulations comprising effective doses of live vaccine and interferon. Finally, the present invention provides methods of administering interferon together with live vaccines to young avians to effectively overcome the interfering effects of maternal antibodies.

Abstract: The present invention provides an improved adjuvant formulation and a process for producing said adjuvant. The adjuvant comprises an ISCOM structure comprising a saponin, said ISCOM structure being devoid of additional detergent.

Abstract: The invention concerns a method for preparing aloin which consists in extracting from a substance containing aloe, in particular the yellow sap of aloe or a derived product, in the presence of an aliphatic diol or triol with low molecular weight, for instance glycerol or a glycol, followed by a purification by crystallization in an alcohol. The invention is useful for industrial preparation of aloin.

Abstract: An immunomodulator having suppressive activity on IgE antibody production is provided and contains bacterial cells, or their decomposition materials. It can be taken as a food. Bacterial cells such as Corynebacterium, Brevibacterium, Microbacterium, or bacterial cells of mutant strains of these bacteria, or decomposition products of these bacteria are used.

Abstract: A protein obtainable from a non pathgenic microorgansim, said protein having mucosa binding promoting activity and a molecular weight of 20-40 kD is disclosed. Application of such a protein or a peptide derived therefrom in a method of screening non pathogenic microorganisms for a microorganism capable of specifically binding mucosa, said method comprising detection in a manner known per se of the presence of a particular protein on or in a microorganism or in a culture of microorganisms, said particular protein being the already defined protein. Kits suitable for such a screening method are also disclosed.

Abstract: A contraceptive and/or HRT (hormone replacement therapy) kit comprising sequential daily dosage units each containing as the sole contraceptively effective ingredient a progestogen, or as the effective ingredient for HRT a progestogen with or without an estrogen or an estrogen only, and further two or more dosage units comprising an anti-progestogen. The present invention also provides contraceptive and HRT methods comprising administering daily dosage units of a progestogen and anti-progestogen.

Abstract: W/O or O/W stable dispersions are formed by mixing an oily phase and an aqueous phase when the dispersion is stabilized with cubic gel particles formed by the combination of two amphiphilic compounds, one of the amphiphilic compounds being capable of forming a lamellar phase in the presence of water, and the other being capable of forming an inverse hexagonal phase in the presence of water.

Abstract: A formulation consisting of sodium bicarbonate, sodium carbonate and trisodium phosphate in aqueous solution is applied topically to treat an array of skin and tissue problems. The solution offers antibacterial, antiseptic, anti-fungal, and healing properties to skin scratches, cuts, sores, and fungal infected nails. In addition, the solution dries as a thin film to the applied surfaces, continuously providing antibacterial, anti-fungal and antiseptic activity beneath the protective film long after it has been applied.

Abstract: The invention concerns a new pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I in which R1 is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R2, R3 and R4 denote independently of one another hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group whereby two of the residues R2, R3 and R4 can together form a C2-C5 alkylene group which, if desired, can be substituted with an —O—, —S— or NR5 group, in which R5 is hydrogen, a C1-C5 alkyl group, a C3-C6 cycloalkyl group or a C1-C5 hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.

Abstract: The present invention relates to a combination for surface treatment of a substrate, e.g. a nonwoven web, used in personal care product applications. The surface treatment combination not only provides adequate fluid handling properties, but also provides a topical delivery system effective in depositing a thin, tenacious and substantially continuous coating of a botanical extract on skin by an aqueous emulsion mediated dissolution of the agent from a substrate with subsequent transfer and deposition onto the skin. Coatings of the botanical extract on the skin resist removal, thereby preventing damage to the natural skin barrier and providing a protective barrier against chemically- and biochemically-induced skin damage.

Abstract: The present invention is directed to a wildlife attractant comprised of an extract from the fruit of the hedge apple tree and methods for using the attractant to attract deer and cover the scent of a human user.

Abstract: A stable medicated animal care formulation including, by weight; (a) 0.1-10% of an active agricultural ingredient, of an animal care and/or veterinary reagents, (b) 0.0002-40% of a microemulsion concentrate including: (i) 0-10% of a castor oil ethoxylate or tristyryl phenol ethoxylate, (ii) 0-1% of an ethoxylated phosphoric acid as pH buffer, (iii) 0.0002-4% of a N—C8-C18 alkyl pyrrolidone and (iv) 0-6% of a N—C1-C4 alkyl pyrrolidone, (c) a surfactant with shampoo properties, and (d) water, wherein (c)+(d) is 50-99.4%.

Abstract: The present invention features a sustained-release microcapsule for long-term pest controlling. In general, a microcapsule has a capsule core including active pest-control ingredients and diluents, and a capsule shell which physically separates the capsule core from the surrounding medium. Diluents are arranged to entrap active ingredients therein and to provide resistance to mass transfer of the active ingredients therethrough. The capsule shell generally includes the shell pores and provides additional resistance to mass transfer of the active ingredient therethrough. Diluents are selected from a class of material such that the mass transfer resistances existing in the capsule core and/or capsule shell depend on the temperature of the surrounding medium.

Abstract: A vascular graft comprising Vascular Endothelial Growth Factor (VEGF) and/or Platelet Derived Growth Factor (PDGF) for enhanced site-specific angiogenesis and methods thereof are disclosed. At least one VEGF, PDGF or angiogenesis factor is incorporated into the vascular graft to facilitate enhanced angiogenesis so as the cells are stimulated to migrate to environments having higher concentration of growth factors and start mitosis.

Abstract: A controlled release system for multiphasic, in vivo release of therapeutic amounts of botulinum toxin in a human patient over a prolonged period of time. The controlled release system can comprise a plurality of botulinum toxin incorporating polymeric microspheres.

Abstract: An antiinfective-free formulation for prophylactic traetment of mastitis in dry cows comprises a seal formulation having approximately 65% by weight of bismuth sub-nitrate in a gel based on aluminum stearate. The seal formulation is prepared by adding the bismuth sub-nitrate to the gel base in at least two separate stages.

Abstract: An edible product in accordance with the present invention involves an edible inner component made from a first material and an edible outer cover component substantially completely encapsulating the edible inner component. In one form of the invention, the inner component is in the form of a hairball treatment for cats and the outer component is a dough-like material. A system for producing the edible product includes a first material source for supplying a first edible material to form the inner component of the edible product, a second material source for supplying a second edible material to form the outer component of the edible product, and an extruder for continuously coextruding the first edible material and the edible second material to produce an elongated rope of edible product. A crimping apparatus receives the longitudinal rope extruded from the extruder for crimping the longitudinal rope to separate the longitudinal rope into individual edible products.

Abstract: The present invention provides improved chlortetracycline-containing animal feed compositions and processes and apparatuses for their preparation. In certain embodiments, raw fermentation broth comprising chlortetracycline is divided into two portions. The first portion is mixed with a compound that complexes chlortetracycline. The second portion is acidified and the solids are removed. The acidified liquid is treated with a complexing agent to produced a chlortetracycline complex. The first and second portions thus treated are then mixed and the mixture is passed on to a filter press or other means for separation of the solids to produce a wet cake comprising complexed chlortetracycline. In alternative embodiments, the second portion may be acidified and filtered and admixed with the first portion prior to the complexing step. The resulting mixture is passed on to a filter press or other means for separation of the solids.

Abstract: A treatment patch includes a patch body having a contacting surface for placing on a skin surface of a treating tissues of a user, and a dressing layer which is provided on the contacting surface containing positively charged metallic ions for depolarizing negative ions accumulated under the skin surface of the treating tissues, wherein a far infrared ray emitter disposed on the. patch body for emitting far infrared rays penetrating into the treating tissues through the skin surface so as to provide an ion passway between the skin surface in contact with the dressing layer of the patch body and the treating tissues so as to enhance the depolarization of the positively charged ions of the dressing layer with the negative ions around the treating tissues of the user to relieve pain.

Abstract: Use of auxiliaries to improve the release of ibuprofen from hot melt adhesive compositions.

Abstract: In accordance with the present invention, there are provided composition and methods useful for the in vivo delivery of a pharmaceutically active agent, wherein the agent is associated with a polymeric biocompatible material.

Abstract: A soft capsule containing oil produced by dissolving mastic in oils and fats. The capsule may further contain amphipathic substance, chitin or chitosan. The capsule serves to remove and inhibit helicobacter pyloric bacteria, as well as to remove smell of feces. The soft capsule containing mastic conceals strong and unacceptable taste of mastic, is easy to be ingested, and has long and direct effect to the stomach.

Abstract: A system for releasing a drug specifically in the colon of the gastrointestinal tract, which comprises a drug (b) coated with an organic acid-soluble polymer material (a), and a saccharide (c) which rapidly generates an organic acid by the action of enterobacteria in the lower part of the gastrointestinal tract; a colon-specific drug release oral preparation, which comprises a composition comprising a drug (b) coated with an organic acid-soluble polymer material (a) and a saccharide (c) which rapidly generates an organic acid by the action of enterobacteria in the lower part of the gastrointestinal tract, said composition being coated with an enteric coating polymer material (d). The invention provides a drug release system and a preparation which utilize enterobacteria, which do not form harmful substances due to the release-starting mechanism, show rapid degradation, and have higher colon specificity.

Abstract: Disclosed herein is an implantable or insertable therapeutic agent delivery device comprising a coating material provided on at least a portion of said device, said coating material prohibiting substantial release therefrom of a therapeutic agent at or below about a physiological pH and allowing substantial release therefrom of a therapeutic agent at or above about said physiological pH. Also disclosed herein are coating materials for the implantable or insertable therapeutic agent delivery device. The coating materials are preferably polymers derivatized to contain moieties that are cationically charged at a pH below their pKa values and which thus can attract negatively charged therapeutically agents at pH values below their pKa values and which become predominantly uncharged at pH values above about their pKa values and thus substantially release the negatively charged therapeutic agents at such pH values, which are preferably about physiological pH.

Abstract: A method of making a dosage device comprises mixing a suspension concentrate comprising at least one active ingredient which is in solid form at 25° C., and which has an average particle size of less than 10 microns, in a carrier liquid in which the active ingredient is non-soluble or sparingly soluble, and a drying agent for the carrier liquid. The drying agent takes up at least some of the carrier liquid of the suspension concentrate, thereby to dry the active ingredient at least partly and to obtain a mixture comprising the active ingredient and the drying agent. The mixture is compressed into at least one unitary dosage device.

Abstract: Disclosed is a method for preparing sustained release microparticles which release a physiologically active substance for long periods of time. The sustained release microparticles are prepared through a multi-emulsion process. A drug of interest is dissolved or dispersed in each of at least two oils to give at least two primary oil phases or emulsions. Each oil phase or emulsion contains a biodegradable polymer. The least two primary oil phases or emulsions are dispersed in one aqueous phase, synchronously or in succession. From the drug-dispersed solution, the organic solvents are removed to produce microparticles. Therefore, the drugs such as leutenizing hormone releasing hormones can be continuously released in vivo for prolonged periods of time, bringing about an improvement in the therapeutic effect.

Abstract: The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and paclitaxel. Also, provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

Abstract: Dry-eye syndrome and other dryness effects of glandular malfunction are treated orally by a combination which includes a source of omega-3 fatty acid, a source of omega-6 fatty acid, vitamin A, vitamin B6, a source of magnesium and a water-soluble antioxidant. The preparation preferably is contained in a capsule. In a preferred form of the preparation and of the method, the preparation also includes mucin and cold water fish oil. The fatty acids preferably are contained in blackcurrant seed oil, and the water-soluble antioxidant is preferably in the form of vitamin C.